Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

517 ARTÍCULOS , VIENDO DEL 376 AL 390

Relevance of Minor Neuropsychological Deficits in Patients With Subjective Cognitive Decline

Stark M, Wolfsgruber S, Kleineidam L, Frommann I, Altenstein S, Bartels C, Brosseron F, Buerger K, Burow L, Butryn M, Ewers M, Fliessbach K, Gabelin T, Glanz W, Goerss D, Gref D, Hansen N, Heneka MT, Hinderer P, Incesoy EI, Janowitz D, Kilimann I, Kimmich O, Laske C, Munk MH, Perneczky R, Peters O, Preis L, Priller J, Rauchmann BS, Rostamzadeh A, Roy-Kluth N, Sanzenbacher C, Schneider A, Schott BH, Spottke A, Spruth EJ, Teipel S, Vogt IR, Wiltfang J, Duzel E, Jessen F, Wagner M.

Neurology. 2023 Nov 21;101(21):e2185-e2196. doi: 10.1212/WNL.0000000000207844. Epub 2023 Oct 11.

Biomarkers in Alzheimer's disease: role in early and differential diagnosis and recognition of atypical variants

Dubois B, von Arnim CAF, Burnie N, Bozeat S, Cummings J.

Alzheimers Res Ther. 2023 Oct 13;15(1):175. doi: 10.1186/s13195-023-01314-6.

MRI and Clinical Biomarkers Overlap between Glaucoma and Alzheimer's Disease

Martucci A, Di Giuliano F, Minosse S, Pocobelli G, Nucci C, Garaci F.

Int J Mol Sci. 2023 Oct 5;24(19):14932. doi: 10.3390/ijms241914932.

Systematic review: fluid biomarkers and machine learning methods to improve the diagnosis from mild cognitive impairment to Alzheimer's disease

Blanco K, Salcidua S, Orellana P, Sauma-Pérez T, León T, Steinmetz LCL, Ibañez A, Duran-Aniotz C, de la Cruz R.

Alzheimers Res Ther. 2023 Oct 14;15(1):176. doi: 10.1186/s13195-023-01304-8.

Accelerating Alzheimer's therapeutic development: The past and future of clinical trials

Boxer AL, Sperling R.

Cell. 2023 Oct 26;186(22):4757-4772. doi: 10.1016/j.cell.2023.09.023. Epub 2023 Oct 16.

Phosphorylated tau in Alzheimer's disease

Telser J, Grossmann K, Wohlwend N, Risch L, Saely CH, Werner P.

Adv Clin Chem. 2023;116:31-111. doi: 10.1016/bs.acc.2023.05.001. Epub 2023 Jun 9.

miRNA as an Ultimate and Emerging Diagnostic Approach for the Detection of Alzheimer's Disease

Jain M, Agarwal S, Rana A, Tiwari A, Patil N.

Microrna. 2023;12(3):189-204. doi: 10.2174/0122115366243970230925061819.

T1 and FLAIR signal intensities are related to tau pathology in dominantly inherited Alzheimer disease

Rahmani F, Brier MR, Gordon BA, McKay N, Flores S, Keefe S, Hornbeck R, Ances B, Joseph-Mathurin N, Xiong C, Wang G, Raji CA, Libre-Guerra JJ, Perrin RJ, McDade E, Daniels A, Karch C, Day GS, Brickman AM, Fulham M, Jack CR Jr, la La Fougère C, Reischl G, Schofield PR, Oh H, Levin J, Vöglein J, Cash DM, Yakushev I, Ikeuchi T, Klunk WE, Morris JC, Bateman RJ, Benzinger TLS; Dominantly Inherited Alzheimer Network (DIAN).

Hum Brain Mapp. 2023 Dec 15;44(18):6375-6387. doi: 10.1002/hbm.26514. Epub 2023 Oct 23.

ASURE Clinical Trial Protocol: A Randomized, Placebo-Controlled, Proof-of-Concept Study Aiming to Evaluate Safety and Target Engagement following Administration of TW001 in Early Alzheimer's Disease Patients

Oosthoek M, Lili A, Almeida A, van Loosbroek O, van der Geest R, de Greef-van der Sandt I, van Bokhoven P, Sikkes SAM, Teunissen CE, Vijverberg EGB.

J Prev Alzheimers Dis. 2023;10(4):669-674. doi: 10.14283/jpad.2023.107.

The Critical Role of Biomarkers for Drug Development Targeting the Biology of Aging

Owen M, Bose N, Nisenbaum L, Partrick KA, Fillit HM.

J Prev Alzheimers Dis. 2023;10(4):729-742. doi: 10.14283/jpad.2023.111.

Two-Year Prognostic Utility of Plasma p217+tau across the Alzheimer's Continuum

Feizpour A, Doré V, Doecke JD, Saad ZS, Triana-Baltzer G, Slemmon R, Maruff P, Krishnadas N, Bourgeat P, Huang K, Fowler C, Rainey-Smith SR, Bush AI, Ward L, Robertson J, Martins RN, Masters CL, Villemagne VL, Fripp J, Kolb HC, Rowe CC.

J Prev Alzheimers Dis. 2023;10(4):828-836. doi: 10.14283/jpad.2023.83.

Exploratory Tau Biomarker Results From a Multiple Ascending-Dose Study of BIIB080 in Alzheimer Disease: A Randomized Clinical Trial

Edwards AL, Collins JA, Junge C, Kordasiewicz H, Mignon L, Wu S, Li Y, Lin L, DuBois J, Hutchison RM, Ziogas N, Shulman M, Martarello L, Graham D, Lane R, Budd Haeberlein S, Beaver J.

JAMA Neurol. 2023 Dec 1;80(12):1344-1352. doi: 10.1001/jamaneurol.2023.3861.

Required improvements for cerebrospinal fluid-based biomarker tests of Alzheimer's disease

Gaetani L, Chiasserini D, Paolini Paoletti F, Bellomo G, Parnetti L.

Expert Rev Mol Diagn. 2023 Jul-Dec;23(12):1195-1207. doi: 10.1080/14737159.2023.2276918. Epub 2023 Dec 15.

Molecular biomarkers for vascular cognitive impairment and dementia

Hosoki S, Hansra GK, Jayasena T, Poljak A, Mather KA, Catts VS, Rust R, Sagare A, Kovacic JC, Brodtmann A, Wallin A, Zlokovic BV, Ihara M, Sachdev PS.

Nat Rev Neurol. 2023 Dec;19(12):737-753. doi: 10.1038/s41582-023-00884-1. Epub 2023 Nov 13.

Potential Retinal Biomarkers in Alzheimer's Disease

García-Bermúdez MY, Vohra R, Freude K, Wijngaarden PV, Martin K, Thomsen MS, Aldana BI, Kolko M.

Int J Mol Sci. 2023 Oct 31;24(21):15834. doi: 10.3390/ijms242115834.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias